Get the Daily Brief
Latest Biotech News
Zealand’s amylin analog posts Phase 2 gains – Roche backs tolerability
Zealand Pharma released Phase 2 data for petrelintide, an amylin analog partnered with Roche, showing up to ~10.7% mean weight loss at 42 weeks with what Zealand characterized as "placebo‑like"...
Lilly pushes employers: new programs aim to broaden GLP‑1 access
Eli Lilly launched programs to expand employer coverage and alternative access pathways for its GLP‑1 obesity drugs, including an employer‑focused service and a platform to ease workplace...
Liquid biopsy beyond cancer: cfDNA fragmentomics flags liver disease
Johns Hopkins researchers reported an AI‑driven fragmentomics liquid biopsy that identifies liver fibrosis and cirrhosis from genome‑wide cell‑free DNA (cfDNA) fragmentation patterns. The team...
FDA places partial hold on PepGen’s DM1 trial – shares tumble
The U.S. Food and Drug Administration placed a partial clinical hold on PepGen’s Freedom2 Phase II program testing PGN‑EDODM1 in myotonic dystrophy type 1 (DM1), citing questions about preclinical...
Evo 2: DNA foundation model scales genome design across life
Researchers published Evo 2, a generative DNA foundation model trained on genomes from more than 100,000 species, and demonstrated its ability to identify disease‑causing human variants and design...
UCLA builds next‑gen CAR‑T to breach solid tumor resistance
UCLA scientists reported a next‑generation CAR‑T cell engineered to overcome immunosuppressive barriers in solid tumors, addressing a principal limitation that has constrained CAR‑T success...
Zorevunersen reduces seizures dramatically: first Dravet gene therapy data
Clinical trial results published in NEJM showed zorevunersen—an investigational gene regulation therapy for Dravet syndrome—cut seizure frequency by large margins and improved quality‑of‑life...
Illumina adds proteomics to pharma research alliance—50k paired datasets
Illumina announced an expansion of its Alliance for Genomic Discovery, committing to add 50,000 genomes paired with proteomic profiles to the consortium’s dataset, generated by DeCode Genetics...
UCB bets on bispecifics: $1.1bn Antengene license
UCB struck a global licensing deal with Antengene to acquire development and commercialization rights to ATG-201, a CD19/CD3 bispecific T‑cell engager for autoimmune diseases. Antengene will run...
FDA surprises PepGen: partial hold on DM1 Phase II
The FDA placed a partial clinical hold on PepGen’s Freedom2 Phase II trial of PGN‑EDODM1 for myotonic dystrophy type 1 (DM1), citing concerns in preclinical pharmacology and toxicology data rather...
Illumina expands genomic alliance: adds proteomics to 50,000 genomes
Illumina announced an expansion of the Alliance for Genomic Discovery by adding 50,000 genomes paired with proteomic data to the consortium dataset. DeCode Genetics will generate the proteomics...
Zealand’s amylin posts phase‑2: tolerability touted by Roche partner
Zealand Pharma released Phase 2 results for petrelintide, an amylin analog partnered with Roche, showing mean weight loss up to 10.7% at 42 weeks and a tolerability profile the partners described...
Oral GLP‑1 era begins: pills arrive as employers get new access pathways
The oral GLP‑1 landscape is shifting: Novo Nordisk rolled out an oral form of its GLP‑1 weight‑loss drug and Eli Lilly’s oral candidate orforglipron nears approval, marking a transition from...
AI liquid biopsy spots liver disease: fragmentomics moves beyond cancer
Researchers at Johns Hopkins unveiled an AI‑driven liquid biopsy that uses genome‑wide cfDNA fragmentation patterns—fragmentomics—to detect liver fibrosis, cirrhosis, and other chronic liver...
FDA pivots on advisory panels and single‑trial defaults… industry asks for clarity
A senior FDA official publicly questioned the role and efficiency of advisory committees, calling some panels 'costly' and 'slow,' while industry groups such as ACRO have urged the agency to...
Atavistik doubles down: Series B extension funds HHT clinical push
Atavistik Bio extended its Series B with an additional $40M, bringing the round to $160M to advance its allosteric programs for blood disorders, including a lead candidate targeting hereditary...
Zorevunersen slashes seizures: gene therapy shows unprecedented Dravet results
Clinical trials led by UCL and Great Ormond Street Hospital reported that zorevunersen, a gene‑regulatory therapy for Dravet syndrome, produced dramatic seizure reductions—between ~59% and 91%...
New immunotherapy routes: CAR‑T for solids and a proteomic target to boost immunogenicity
UCLA researchers reported a next‑generation CAR‑T design engineered to resist solid‑tumor immunosuppression and show activity in preclinical models, addressing a major barrier to CAR‑T efficacy...
Oral GLP-1s Arrive: Pills, approvals and the rebound question
Novo Nordisk pushed the oralization of its GLP-1 platform into the clinic this year with a tablet version of Wegovy and competitors are closing in. Eli Lilly’s oral orforglipron is expected to...
FDA rethinks process: Advisory panels and single-trial default under scrutiny
A senior Food and Drug Administration official questioned longstanding external advisory committee processes as “costly” and slow, signaling an internal push to streamline review procedures....